6:35 PM
 | 
May 01, 2013
 |  BC Extra  |  Politics & Policy

MEDCAC mixed on cancer diagnostics

CMS's Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) concluded on Wednesday that existing evidence is sufficient to confirm the clinical validity of DNA- or RNA- based testing to predict the tissue of origin for cancer of unknown primary site. However, the panel was less confident there is sufficient evidence to determine if the tests affect health...

Read the full 264 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >